Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
BRISTOL MYERS SQUIBB CO | EVP,Chief Med.Offr.,Drug Dev. | Common Stock, $0.10 par value | 62.1K | $3.4M | $54.68 | Nov 1, 2024 | Direct |
BRISTOL MYERS SQUIBB CO | EVP,Chief Med.Offr.,Drug Dev. | Common Stock, $0.10 par value | 60.3K | $3.24M | $53.79 | Mar 10, 2024 | Direct |
BRISTOL MYERS SQUIBB CO | EVP,Chief Med.Offr.,Drug Dev. | Market Share Units | 40.6K | $2.19M | $53.79 | Mar 10, 2024 | Direct |
BRISTOL MYERS SQUIBB CO | EVP,Chief Med.Offr.,Drug Dev. | Performance Shares | 61K | Mar 10, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
BMY | BRISTOL MYERS SQUIBB CO | Nov 1, 2024 | 1 | $100K | 4 | Nov 5, 2024 | EVP,Chief Med.Offr.,Drug Dev. |
BMY | BRISTOL MYERS SQUIBB CO | Mar 10, 2024 | 16 | -$734K | 4 | Mar 12, 2024 | EVP,Chief Med.Offr.,Drug Dev. |
BMY | BRISTOL MYERS SQUIBB CO | Jul 1, 2023 | 3 | -$306K | 4 | Jul 5, 2023 | EVP,Chief Med.Offr.,Drug Dev. |
BMY | BRISTOL MYERS SQUIBB CO | Mar 10, 2023 | 18 | -$1.47M | 4 | Mar 14, 2023 | EVP,Chief Med.Offr.,Drug Dev. |
BMY | BRISTOL MYERS SQUIBB CO | Jul 1, 2022 | 3 | -$368K | 4 | Jul 5, 2022 | EVP,Chief Med.Offr.,Drug Dev. |
BMY | BRISTOL MYERS SQUIBB CO | Mar 10, 2022 | 10 | -$356K | 4 | Mar 14, 2022 | EVP,Chief Med.Offr.,Drug Dev. |
BMY | BRISTOL MYERS SQUIBB CO | Jul 1, 2021 | 3 | -$319K | 4 | Jul 6, 2021 | EVP,Chief Med.Offr.,Drug Dev. |